Alerts will be sent to your verified email
Verify Email
ONESOURCE
|
Onesource Specialty
|
Neuland Laboratories
|
Astrazeneca Pharma I
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
-55.95 % | 14.95 % | 17.42 % |
|
5yr average Equity Multiplier
|
2.39 | 1.56 | 1.99 |
|
5yr Average Asset Turnover Ratio
|
0.1 | 0.74 | 0.91 |
|
5yr Avg Net Profit Margin
|
-618.78 % | 13.18 % | 9.65 % |
|
Price to Book
|
3.58 | 12.98 | 29.01 |
|
P/E
|
0.0 | 112.37 | 121.87 |
|
5yr Avg Cash Conversion Cycle
|
-26.64 Days | 38.21 Days | -6.33 Days |
|
Inventory Days
|
721.36 Days | 87.5 Days | 68.19 Days |
|
Days Receivable
|
59.6 Days | 85.17 Days | 35.81 Days |
|
Days Payable
|
492.44 Days | 118.14 Days | 187.52 Days |
|
5yr Average Interest Coverage Ratio
|
-2.85 | 20.78 | 142.38 |
|
5yr Avg ROCE
|
-10.8 % | 17.63 % | 23.84 % |
|
5yr Avg Operating Profit Margin
|
-109.36 % | 21.01 % | 14.57 % |
|
5 yr average Debt to Equity
|
0.94 | 0.15 | 0.0 |
|
5yr CAGR Net Profit
|
-40.0 % | 26.4 % | 4.4 % |
|
5yr Average Return on Assets
|
-19.85 % | 9.87 % | 8.92 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
29.79 % | 32.68 % | 75.0 % |
|
Share Pledged by Promoters
|
25.01 % | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
-7.98 % | -3.54 % | 0.0 |
|
Change in Mutual Fund Holding (3 Yrs)
|
4.44 % | 6.87 % | 3.26 % |
|
Onesource Specialty
|
Neuland Laboratories
|
Astrazeneca Pharma I
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|